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How common and severe are six withdrawal effects from, and addiction to, 
antidepressants? The experiences of a large international sample of patients. 
 
HIGHLIGHTS 
• Over half (55%) of people who had tried to come off or reduce antidepressants report 
some degree of difficulty coming off, with 27% ticking ‘very difficult’ 
• 61% report ‘withdrawal effects’, with 44% of these describing the effects as ‘severe’ 
• 40% report ‘addiction’, with 39% of these describing their addiction as ‘severe’ 
• ‘Anxiety/panic’ (66%) and ‘Irritability (62%) are particularly common 
• Less than 1% had been told anything about withdrawal effects or dependence 
 
ABSTRACT 
Introduction: The incidence and severity of withdrawal effects when coming off 
antidepressants (ADs) have recently received considerable attention. National guidelines on 
the topic have proven to be inaccurate. This paper reports the largest direct-to-patient 
international survey on these issues. 
Methods: Data generated by an online survey from 867 people from 31 countries, who had 
taken ADs continuously for at least one month, and had tried to come off (successfully or 
not) was analysed. 
Results: The majority (59%) had taken ADs for more than three years. Of those who were 
still taking them, 29% had been doing so for at least 20 years. 61% reported some degree of 
withdrawal effects, and 44% of these described the effects as ‘severe’. The most common of 
six listed withdrawal effects were anxiety/panic (66%) and irritability (62%). The most 
common spontaneously reported ‘other’ withdrawal effect was suicidality (2%). 40% 
reported that they felt addicted, with 39% of these describing their addiction as ‘severe’. Over 
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half (55%) reported some degree of difficulty coming off, with 27% ticking ‘very difficult’, 
and 11% ‘very easy’. Duration of treatment was related to withdrawal, addiction and 
difficulty coming off. Younger people experienced more frequent withdrawal effects. Only 
six people (0.7%) recalled being told anything about withdrawal, dependence or addiction by 
the initial prescriber. 
Conclusions: These findings confirm previous studies, using a range of methodologies, 
finding high incidences of withdrawal effects, frequently at severe levels. National 
guidelines, and those of professional organisations, urgently need to be updated to reflect this 
evidence.   
 
1. Introduction 
In the U.K. antidepressant [AD] prescribing has doubled over ten years. By 2016-17 more 
than seven million adults (16% of the adult population) were prescribed ADs in England 
(DHSC, 2018). Similar rates occur in Australia, Belgium, Canada, Denmark, Iceland, 
Portugal, and Sweden (OECD, 2017, 2018), with the highest being in the U.S. (Pratt, Brody, 
& Qu, 2017).  
These high prescription rates do not seem to be explicable in terms of increases in 
depression or help-seeking (Munoz-Arroyo, Sutton, & Morrison, 2006). UK data on 189,851 
GP patients showed that a doubling of prescribing over eight years was probably explained 
by a doubling of prescriptions per patient, rather than by increases in new prescriptions 
(Moore et al., 2009). By 2011, half of AD users in England, about 3.5 million people, were 
taking ADs for longer than two years (Johnson et al., 2012). About half of AD users in the 
U.S. (about 18 million) take them for at least 5 years (Mojtabai & Olfson, 2014). Average 
duration has doubled since the mid-2000s in the U.K. (NHS Digital, 2017) and the U.S. 
(Mojtabai & Olfson, 2014). In the U.K., a third of people taking ADs for more than two years 
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have no clinical need for them (Cruickshank, MacGillivray, & Bruce, 2008). Similar rates of 
apparently unnecessary long-term prescribing occur in Australia (Ambresin et al., 2015) and 
the Netherlands (Eveleigh, 2015). 
Difficulty stopping the drugs because of withdrawal effects might explain why long-term 
prescribing is increasing, including to people who are deemed not to have a clinical need for 
them. The notion of AD withdrawal effects was officially recognised by a ‘consensus panel’ 
funded by drug company Eli Lilly in 1996, and was immediately minimised by creating the 
term ‘discontinuation syndrome’ (Schatzberg et al., 1997), still sometimes unquestioningly 
deployed today. Since then withdrawal from ADs has been portrayed, by guidelines and 
professional bodies, as rare, minimal and brief.  
The President of the UK’s Royal College of Psychiatry (RCP) and the Chair of the RCP’s 
Psychopharmacology Committee recently wrote ‘We know that in the vast majority of 
patients, any unpleasant symptoms experienced on discontinuing antidepressants have 
resolved within two weeks of stopping treatment’ (Burn & Baldwin, 2018). U.S.A guidelines 
similarly claim symptoms ‘typically resolve without specific treatment over 1–2 weeks’ 
(A.P.A., 2010, p. 39).  U.K. guidelines state ‘symptoms are usually mild and self-limiting 
over about 1 week, but can be severe, particularly if the drug is stopped abruptly’ (NICE, 
2009, 1.9.2.1 in CG90). Freedom of Information requests revealed that the current NICE 
guidelines on AD withdrawal are not based on any research studies (Davies & Read, 2019a, 
p. 119). 
Three systematic reviews have now established that such statements and guidelines have 
been minimising the problem (Davies & Read, 2019a; Fava et al., 2015; 2018). The most 
recent systematic review (involving the current author) was undertaken at the request of the 
UK’s All Party Parliamentary Group for Prescribed Drug Dependence, to inform an enquiry 
by Public Health England (an agency of the Department of Health and Social Care). Fourteen 
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studies, including small RCTs and large scale surveys, found that withdrawal incidence rates 
ranged from 27% to 86% with a weighted average of 56%. Four studies produced a weighted 
average of 46% of those experiencing withdrawal effects endorsing the most extreme 
‘severity’ rating. Seven of ten studies with data on duration contradict the U.K. and U.S.A. 
guidelines, by finding that a significant proportion of people who experience withdrawal do 
so for far more than two weeks, and that it is not uncommon for people to experience 
withdrawal for several months. The reviewers (Davies & Read, 2019a, p. 111) concluded: 
We recommend that U.K. and U.S.A. guidelines on antidepressant withdrawal be urgently 
updated as they are clearly at variance with the evidence on the incidence, severity and 
duration of antidepressant withdrawal, and are probably leading to the widespread 
misdiagnosing of withdrawal, the consequent lengthening of antidepressant use, much 
unnecessary antidepressant prescribing and higher rates of antidepressant prescriptions 
overall. We also recommend that prescribers fully inform patients about the possibility of 
withdrawal effects.  
The Davies and Read review was sharply critiqued by two psychiatrists who characterised 
it as a ‘War on antidepressants’, claimed that the review had exaggerated the extent, severity 
and duration of withdrawal effects, and disagreed with our call for guidelines to be urgently 
reviewed (Jauhar & Hayes, 2019). Our response carefully documented their ‘many serious 
mistakes and misrepresentations (and/or misunderstandings)’ that led us to describe their 
critique as ‘clearly imbalanced, imprudent and inaccurate’ (Davies & Read, 2019b), an 
assessment shared by a further commentator (Hengartner, 2019).  
Jauhar and Hayes did, nevertheless, raise legitimate concerns about using online surveys 
(such as the one that generated the data for the current paper) to estimate incidences. 
Participants in such surveys are certainly not randomly selected or generalizable to all 
antidepressant users. It is possible, therefore, that they may over-represent dissatisfied or 
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disgruntled patients. We were able to reassure them, however, (Davies & Read, 2019b) that 
in the largest survey 83% believed the antidepressants had reduced their depression (Read et 
al., 2014). In the current survey this was the case for 63% (Read & Williams, 2018).  
Jauhar & Hayes (2019), having corrected what they believed to be the errors in the Davies 
and Read review, proposed that a better estimate of the incidence of withdrawal effects 
among people who try to come off is 44%. This would still represent 3.2 million people in 
England alone. So researchers on both sides of a rather charged debate agree that about half 
(somewhere between 44% or 56%) of people experience withdrawal effects when they try to 
come off ADs. 
The current paper reports further findings from an international survey about positive and 
negative effects of ADs (Read & Williams, 2018). The survey had found that withdrawal 
effects were reported by 59%, and addiction by 40% of 1,431 AD users from 38 countries. 
The current paper, analysing only responses from participants who had tried to come off or 
reduce their ADs, reports on the frequency of six specific types of withdrawal effects, on self-
reported ease/difficulty of coming off, and on whether patients were told about withdrawal; 
plus analyses by demographics, treatment duration and drug type. 
Very few studies have reported on how often people are informed about withdrawal 
effects when being prescribed the drugs (Read, Cartwright & Gibson, 2018; Read, Gee et al., 
2018). This is only the second survey to report on ease/difficulty withdrawing (Read, Gee et 
al., 2018). This is the first large survey to report the incidence or severity of specific 
withdrawal effects. A recent analysis of 110 postings on a withdrawal website may be the 
next largest report on specific withdrawal effects (Stockman et al., 2018). RCTs tend to have 
artificially short treatment durations, small sample sizes, rarely report on withdrawal at all, let 
alone on specific withdrawal symptoms, and also tend not to analyse by demographics 
(Davies & Read, 2019a, 2019b). It is hoped that mapping the most common withdrawal 
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effects might assist in the identification of patients experiencing withdrawal, and that any 
links with demographic groupings might lead to extra caution in prescribing, and while 




The AD sections of ‘The Experiences of Anti-depressant and Anti-psychotic Medication 
Survey’ (see Read & Williams, 2018) were based on the New Zealand ‘Views on 
Antidepressants’ questionnaire (Gibson, Cartwright & Read, 2016; Read, Cartwright & 
Gibson, 2014, 2018; Read et al., 2015). These sections generate quantitative data (yes/no and 
multiple-choice questions) and qualitative data (open-ended questions) about: the prescribing 
experience, positive and negative effects of ADs, beliefs about causes of depression, 
withdrawal experiences, and demographics. Questions were based on the research literature 
pertaining to each topic. 
The questions generating the data which is the main focus of the current paper were: 
 
‘Please rate the following side effects you may have experienced as a result of taking the 
anti-depressant’ – followed by a list of 14 effects including ‘Withdrawal Effects’ and 
‘Addiction’ and the following response options: ‘Not at all’ ‘Mild’ ‘Moderate’ ‘Severe’. 
 
When trying to withdraw from anti-depressants, did you experience an increase in the 
following: ‘Nausea’ ‘Brain Zaps’ ‘Dizziness’ ‘Anxiety/Panic’ ‘Irritability’ ‘Nightmares’ 





‘How easy was it for you to come off your medication?’ – ‘Very Difficult’  ‘Difficult’ 
‘Somewhat Difficult’ ‘Somewhat Easy’ ‘Easy’ ‘Very Easy’. 
 




Of the 2,346 who responded, 2,133 had taken ADs. Of these, 42 were deleted because 
they ticked ‘no’ when asked if they met the criteria: ‘I have been taking or have previously 
taken antidepressant medication continuously for at least one month for any reason’; ‘I am 
aged 18 or older’; and ‘I am not currently compulsorily detained in a psychiatric hospital’. Of 
the remaining 2,091, the 44 that responded to ‘What is the name of your current or most 
recent anti-depressant medication?’ with a drug other than antidepressants were deleted. 
There were 39 responses from the same Internet Protocol address as another response, 
indicating use of the same computer. Of these 39, 33 were deemed a repeat response (based 
on identical demographics or similar responses) and were omitted. Of the remaining 2,014, 
497 completed insufficient questions in the AD sections, leaving 1,517. Of these, 499 had 
taken antipsychotics as well as ADs, and were excluded (to avoid potential confusion, or 
interactions, between withdrawal from the two types of drugs). Finally, 151 of the remaining 
1018 ticked ‘No’ to the question ‘Have you ever reduced or tried to come off your anti-
depressant medication?’ These 151 were deleted because withdrawal effects could not occur 
under those circumstances. This left 867. 
 
2.3. Data Analysis 
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Relationships between variables were analysed using chi-squares (X2) and spearman rank 
correlations (rho). Differences between means on continuous variables (e.g. age) were 
analysed with two-tailed t-tests. Because of the large number of analyses the significance 
level was set at p < .01 rather than the traditional p < .05. 
 
3. Results 
3.1. Sample characteristics 
 Respondents’ were aged 18 to 77 years with an average of 45.8 (sd = 13.6); and 70.8% 
were women. IP addresses showed that the respondents lived in 31 countries, most commonly 
Australia (408; 47.1%) (from where the survey was conducted), the UK (152; 17.5%), and 
the USA (115: 13.3%). Seven other countries had more than 10 respondents: New Zealand 
(29), Germany (36), Denmark (21), Canada (20), Ireland (18), the Netherlands (11), and 
Sweden (11). Twenty one contributed up to eight participants: Albania, Algeria, Austria, 
Belgium, Bosnia, Bulgaria, Croatia, Faroe Islands, Finland, Greece, India, Italy, Lithuania, 
Norway, Poland, Portugal, Slovakia, Slovenia, South Africa, Spain and Switzerland.  
When asked ‘Do you think you were prescribed anti-depressant medication to treat 
depression?’ most (84.2%) replied ‘Yes’. More than two thirds (70.0%) thought the drugs 
reduced their depression, and 12.2% thought they made the depression worse. Similarly, 
64.2% reported that Quality of Life was ‘improved’, and 18.3% thought it was made ‘worse’. 
Of the 759 who named their medication(s), the most commonly received SSRIs were 
fluoxetine (16.3%), citalopram (14.0%), sertraline (13.7%), paroxetine (9.0), and 
escitalopram (6.7%). Venlafaxine, an SSNRI, was cited by 7.2% and Tricyclic ADs by 7.9%; 
while 12.1% reported two or more ADs. 
 
3.2. Treatment duration 
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More than half (59.1%) had taken ADs for ‘more than three years’; with 6.4% having 
taken them for ‘two to three years’, 10.3% for ‘one to two years’, 11.0% for ‘six to 12 
months’, and 13.2% for between one and six months. Age was significantly correlated with 
treatment duration (rho = .204, n = 854, p < .001). Women had somewhat longer durations, 
with 62.2% on ADs for more than three years, compared to 52.2% of men. This difference 
did not meet the p < .01 level set for this study (rho = 11.25, df = 5, p = .047).  
Nearly half of the total sample (47.9%) had stopped taking ADs when they completed the 
survey. By analysing only the 452 who were still taking the drugs, duration of treatment 
could be ascertained in more detail than permitted by the five age groupings, by subtracting 
age at first use from current age. Of the 444 who provided current age and age at first use the 
average treatment duration was 14.3 years (sd = 9.1). (58.7% had taken ADs ‘continuously’ 
and 41.2% ‘intermittently). About two thirds (67.3%; 299) had been taking them for at least 
ten years; 28.8% (128) for at least 20 years, and 5.6% (25) for 30 years or more. Women had 
a significantly longer mean treatment duration (15.0) than men (12.4) (t = 2.63, df = 439, p = 
.009). Age was strongly correlated to duration (r = 4.21, n = 444, p < .001).  
Extreme examples include a 61 year old Australia woman and a 58 year old New Zealand 
woman who had both been prescribed ADs as 14 year old girls and had been on them 
continuously for 47 and 44 years.  A 68 year old man in the USA had taken ADs 
intermittently for 45 years, since the age of 23. A 73 year old Australian woman had taken 
ADs intermittently for 53 years, since the age of 20.  
 
3.3. Withdrawal effects 
Of the 803 responding to the question ‘Please rate the following side effects you may have 
experienced as a result of taking the anti-depressants’, 309 (38.5%) responded ‘not at all’ to 
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‘withdrawal effects’. Of the 494 (61.5%) reporting some degree of withdrawal effects, 31.2% 
reported them to be ‘mild’, 24.5% as ‘moderate’ and 44.3% as ‘severe’.  
Experiencing some degree of withdrawal effects was strongly related to length of time 
taking ADs (X2 = 23.03, df = 5, p < .001). For example, 46.8% of those who had taken ADs 
for six months or less reported withdrawal effects, compared to 67.4% of those on ADs for 
more than three years. Similarly, amongst those with some degree of withdrawal effects, their 
severity was strongly correlated with treatment duration (rho = .23, n = 494, p < .001). 
The mean age of people with some degree of withdrawal effects (43.7) was significantly 
younger than those who did not experience withdrawal (48.5) (t = 4.86, df = 806.2, p < .001). 
Age was, however, unrelated to severity.  Gender was unrelated to incidence or severity.  
 
3.3.1. Specific withdrawal effects. Between 787 and 798 responded to questions about six 
specific withdrawal effects, worded as ‘When trying to withdraw from antidepressants did 
you experience an increase in …?’ with possible responses of ‘no increase’, ‘a slight 
increase’ and ‘a big increase’. Of the 764 who responded to all six questions, most (79.2%) 
reported at least one withdrawal effects, 54.1% reported three or more and 15.8% reported all 
six. The mean number of effects was 2.83 (sd = 2.10). The number of withdrawal effects was 
unrelated to gender but was negatively related to age (rho = - .21, n = 763, p < .001). 
Table 1 shows that the six were experienced, to some degree, by between 65.6% 
(‘Anxiety/panic’) and 34.8% (Nausea). Women were significantly more likely than men to 
experience Dizziness (X2 = 8.39, df = 1, p = .004). The mean age of those experiencing four 
of the six withdrawal effects was significantly lower than those not experiencing them (see 
Table 1), with the largest difference being for Nausea (41.0 vs 47.8 years; t = 7.15, df = 
637.2, p < .001). Length of time taking ADs was strongly related to all six, five at the p < 




TABLES ONE & TWO ABOUT HERE 
 
 One or more ‘other’ withdrawal effects were identified by 193 people (see Table 2). 
Some examples: 
Suicidality and self-harm. 
I had body aches and pains, flu like symptoms, constant malaise. 
Derealization, depersonalization, intrusive thoughts, cramps, nerve pain, exhaustion, 
vision problems, sexual problems, cognitive problems, constant fear, great grief, 
suicidal thoughts, high anxiety, trouble connecting to others, constant crying. 
Severe diarrhea, severe exhaustion, severe headaches. 
The electric shocks through my whole body from toes to fingertips to brain, for a few 
seconds every few seconds, all day even when lying down. They gradually 
stopped after about 4 weeks. 
Permanant damage - brain zaps and sound sensitive, years after stopping. 
 
3.4. ‘Addiction to the medication’ 
Of the 803 responding to the side effects questions 320 (39.9%) reported some degree of 
‘addiction to the medication’. Of these 320, 113 (35.3%) described the addiction as ‘mild’, 
25.3% as ‘moderate’ and 39.4% as ‘severe’.  
Experiencing some degree of addiction was strongly related to treatment duration (X2 = 
40.90, df = 5, p < .001). For example, 25.7% of those who had taken ADs for six months or 
less reported addiction, compared to 48.1% of those on them for more than three years. 
Treatment duration was also strongly correlated with severity of addiction (rho = .30, n = 
310, p < .001). 
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Gender and age were unrelated to incidence or severity of addiction. Unsurprisingly, 
incidence of addiction was highly related to incidence of withdrawal (X2 = 148.07, df = 1, p < 
.001). Similarly, severity of addiction was highly related to severity of withdrawal (X2 = 
111.32, df = 4, p < .001).  
 
3.5 ‘How easy was it’? 
Of the 797 who responded to ‘How easy was it for you to come off your medication?’ on a 
six point scale (1 = ‘very difficult’, 6 = ‘very easy’), 10.9% ticked ‘very easy’, and 27.2% 
‘very difficult’. Overall, 45.4% found it ‘easy’ to some degree and 54.6% experienced some 
difficulty (see Table 3). 
Difficulty coming off was not significantly related to age or gender. It was, unsurprisingly, 
strongly related to incidence and severity of both withdrawal effects and addiction, with all 
four relationships at the p < .001 level. For example, 89.8% of those who found it ‘very 
difficult’ to come off experienced withdrawal effects, compared to 18.4% who found it ‘very 
easy’. It was also strongly related to each of the six withdrawal effects, all at the p < .001 
level, with rhos ranging from 0.43 (Anxiety) to .50 (Dizziness). 
 
TABLES 3 & 4 ABOUT HERE 
 
3.6. Drug types 
The four most frequently cited SSRIs, the SSNRI venlafaxine, and tricyclics (combined) 
were compared. There were no significant differences in incidence of ‘withdrawal effects’ 
overall or ‘addiction’. Paroxetine, however, produced reports of significantly greater severity 
of withdrawal effects, at the p < .001 level than sertraline and tricyclics, and at the p < .01 
level compared to citalopram and fluoxetine. Each of the six specific withdrawal effects 
occurred significantly more frequently with paroxetine than with between one and four of the 
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other drug types (see Table 4). Brain zaps were reported more frequently with venlafaxine 
compared to sertraline and tricyclics.    
 
3.7. Information 
Only 36.2% reported that they had been told anything about ‘any possible side effects’. 
When participants were asked what specific side effects they recalled being told about only 
six (0.7%) reported anything to do with withdrawal, dependence or addiction, including: ‘not 
to stop taking them all at once’, ‘they were habit forming and I could not stop taking 
abruptly’, and ‘need to go off gradually.’  
When asked ‘Did the doctor tell you how long you should take the antidepressants for?’ 
52.3% replied ‘no’. Gender and age were unrelated. Of those who were told anything, 6.6% 
were told to take them for three months or less, 35.5% were told between three and 12 
months; 18.1% for more than a year, and 39.9% ticked ‘until you feel better’. Gender and age 
were unrelated to the recommended duration. 
 
4. Discussion   
4.1. Treatment duration 
The long treatment durations reflect the large increases in duration noted earlier. A recent 
UK online survey of 752 AD users found that 36% had been taking them for at least five 
years, and 26% expected to be on them forever (Read, Gee, Diggle, & Butler, 2018). 
 
4.2. Withdrawal symptoms 
The proportion of people experiencing some degree of withdrawal effects reported here 
(61.5%) is even higher than the 55% previously reported for this survey (Read & Williams, 
2018), and the 55% found in a New Zealand survey with identical methods (Read, 
Cartwright, & Gibson, 2018), because the current analyses excluded participants who had 
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never tried to reduce or discontinue. These rates are also somewhat higher than traditional, 
drug company sponsored drug trials, which use artificially short treatment periods of 8 to 12 
weeks (Davies & Read, 2019a). The weighted average of all studies to date, using a range of 
methodologies is 56% (Davies & Read, 2019a). The finding that younger people are more 
likely to experience withdrawal effects was not found in the New Zealand survey and has not 
been tested by drug trials, which tend to ignore demographics. Amongst those reporting 
withdrawal effects the percentage describing them as severe (44.3%) is similar to the 
percentage in the New Zealand survey (46%) and to two other surveys, by Groot & van Os 
(2018) - 51%, and Davies, Pauli and Montagu (2018) - 43%.   
This is the first large survey to report the incidence or severity of specific withdrawal 
effects. A smaller but valuable analysis, of 110 postings on an antidepressant website 
(Stockman et al., 2018), found that 94% reported one or more ‘Psychological’ withdrawal 
effect, for example: ‘Brain fog’, anxiety, depression, feeling suicidal, irritable, feeling 
‘lousy’, ‘emotional numbness’, and pessimism, (p. 178). Two thirds (66%) reported at least 
one ‘Neurological’ effect, for example: Dizziness, ‘brain zaps’, ‘whoosh in ears’, ringing 
ears, paraesthesia, ‘needles under skin’, sensitive to light, buzzing sound, and burning 
sensation. Less than half (43%) reported one or more of the following ‘Gastrointestinal’ 
effects: Nausea, bloated, diarrhoea, constipation, acid reflux, stomach cramps, appetite 
changes, sensitivity to food.  
The six symptoms measured in the current study have been identified in drug trials but 
with smaller frequencies, due largely, again, to the atypically short treatment periods.  The 
extent of the underestimation by drug trials is demonstrated by the fact that 38.1% of those on 
ADs for one to three months reported irritability when withdrawing, compared to 72.4% of 
those on them for the more typical duration of three years or more. The current findings, 
including more than 60% reporting anxiety/panic and irritability, need to be replicated with 
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equally large samples, but including some of the effects identified by the open request for 
‘other’ withdrawal effects, such as suicidality, insomnia and sexual dysfunction. 
 
4.3 Addiction 
The issue of whether ADs should be considered addictive has polarised opinion. Many 
recipients report that they are addictive. The 40% rate of self- reported ‘addiction to the 
medication’ is slightly higher than the 37% previously reported from this survey when those 
who had never tried to come off were included (Read & Williams, 2018), but clearly higher 
than the 27% self-reported in the New Zealand survey (again including those who had never 
tried to come off). In both studies duration of treatment was strongly correlated with 
addiction. A review of studies of patient-centred perspectives found fear of addiction to be 
‘the most frequently mentioned reason for a negative opinion of antidepressants’ (Gibson et 
al., 2014, p. 83). Among 493 AD users in Denmark, 56% agreed with ‘Your body can 
become addicted to antidepressants’ (Kessing et al. 2005). Of 192 people in the Netherlands 
who had been taking ADs for six months, 30% reported that ADs are ‘addictive’ (Hoencamp 
et al., 2002). It seems that somewhere between a quarter and a half of AD users experience 
ADs as addictive, with the proportion increasing with treatment duration.  
Nevertheless, many of the researchers who find these high levels of self-reported addiction 
describe the patients’ experiences and views as ‘erroneous beliefs’ and ‘negative attitudes’ 
and worry that they may that impede medication compliance (e.g. Bogner et al., 2009; 
Hoencamp et al., 2002; Kessing et al., 2005). Similarly, the only reference to the issue in the 
American Psychiatric Association Practice (A.P.A.) Guideline for depression (2010) is 
‘Common misperceptions about antidepressants (e.g. they are addictive) should be clarified’. 




The Diagnostic and Statistical Manual for Mental Disorders (A.P.A., 2013) requires that 
two of eleven criteria are met for ‘substance dependence’. The current study, and the large 
New Zealand survey, suggest that ADs meet four of them: ‘Withdrawal manifesting as a 
characteristic syndrome’, ‘Wanting to cut down or quit but not being able to do it’, 
‘Continued use despite persistent or recurring social or interpersonal problems caused or 
made worse by substance use’ and ‘Stopping or reducing important social, occupational, or 
recreational activities due to substance use.’ 
In 2012 the Nordic Cochrane Centre reviewed 45 papers on benzodiazepines and 31 
papers on SSRIs and concluded that ‘Withdrawal reactions to SSRIs appear to be similar to 
those for benzodiazepines; referring to these reactions as part of a dependence syndrome in 
the case of benzodiazepines, but not selective serotonin re-uptake inhibitors, does not seem 
rational’ (Nielsen, Hansen, & Gotzsche, 2012).  
If one includes physical cravings in one’s addiction criteria then ADs are not addictive. 
Similarly they do not, at first glance, have what the recent Public Health England report 
defines as the distinguishing characteristic of ‘addiction’, namely ‘a compulsive 
preoccupation to seek and take a substance despite consequences’ (Tayler et al., 2019, p 8). 
However, if the preoccupation includes a compulsion to put as end to the withdrawal effects 
then there is an argument that ADs do meet that particular criterion for addiction.  
 
4.4 Easy or difficult 
The range of responses regarding how easy it was to come off broadly parallels the finding of 
a large UK survey in which 20% found it ‘very easy’, 51% ‘fairly easy’; and 29% ‘not easy at 
all’ (Read, Gee, et al., 2018). The same survey also found that while 68% took less than three 
months to come off, 21% took between three and six months; 6% took between six and 12 
months; and 5% took more than a year. Such distributions reveal important individual 
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differences. Even though duration of being on ADs is, in the current study, strongly 
predictive of how difficult it is, differences in withdrawal effects will still occur between 
people who have taken ADs for similar amounts of time. Therefore, there must be no ‘one 
size fits all’ approach to the time necessary to withdraw or how much support is needed. 
 
4.5. Drug types  
The findings regarding drug types confirm the findings of drug trials and the New Zealand 
survey (Read, Cartwright, & Gibson, 2018) that ADs with a shorter half-life, like paroxetine 




The finding that only six people (0.7%) recalled being told anything about withdrawal 
effects is alarming. It is matched by the only other data on this important issue, from the New 
Zealand survey, in which nine out of 1,829 people (0.9%) recalled such information being 
imparted (Read, Cartwright, & Gibson, 2018). This breaches the ethical principle, binding on 
all health professionals, of ‘informed consent’.  
 
4.7 On a more positive note 
Alongside the disquieting findings about withdrawal effects and lack of information, it 
must be noted that a large majority of participants (70%) considered that antidepressants 
reduced their depressive symptoms, and improved their quality of life (64%).  Findings that 
the majority of improved cases are the result of placebo effects (Jakobsen et al., 2017; Kirsch 
et al.  2008) cannot detract from the reality that most people in the sample felt better and 
believed this was a result of the drugs. Similarly it should also be underlined that 38.5% of 
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the sample did not experience withdrawal effects, and 19.2% reported only mild effects. Thus 




Although this is the second largest sample (and largest international sample) directly 
surveyed, it is a self-selected, convenience sample. Almost the entire sample lived in Europe, 
North America or Australasia. The over representation of women (70.8%) is not, however, a 
limitation because women are prescribed ADs approximately twice as often as men.  
The excluded subgroups might present specific characteristics lowering the 
representativeness of the final sample. Those leaving the questionnaire without answering all 
the questions might have reduced attentional abilities or increased impulsivity; those also 
taking antipsychotic might present more severe depressive states or comorbidities; those not 
trying to reduce antidepressants might also have unknown specific characteristics 
The high rates of reported withdrawal effects and addiction suggest the sample may be 
biased towards people who found ADs ineffective and had ‘an axe to grind’. However, 70.0% 
reported that the ADs had reduced their depression.  
The study relies on self-report, but so do most drug studies. Some of the reports, however, 
are for events many years ago. Some people may have been given more information about 
withdrawal than they could recall. In fact 42 participants wrote some variation of ‘can’t 
recall’. One 70 year old Australian man, wrote ‘He was always good at discussing side 
effects of all medications he prescribed, however it is so long ago I can't recall what he said’.  
When asked whether they had experienced ’withdrawal effects’ 494 said they had, to some 
extent. However, when asked ‘When trying to withdraw from antidepressants did you 
experience an increase in …?’, without explicitly describing the experiences as ‘withdrawal 
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effects’, 605 reported at least one of the six experiences. It is possible, therefore, that a small 
minority of those reporting the most common experiences, ‘anxiety/panic’ and irritability’, 
while coming off the drugs did not interpret them as withdrawal effects, and/or that they were 
in fact not withdrawal effects. Since 521 reported ‘anxiety/panic’ and 499 reported 
‘irritability’ the most this could apply to is 27 of those reporting the former (5.1%) and five of 
those reporting the latter (1.0%). 
 
6. Conclusions 
The views of ‘experts-by-experience’ in general, and Patient-Reported Outcome Measures 
(PROMs) in particular, are now recognised as crucial to understanding whether mental health 
services are beneficial and safe (Gibson et al., 2014, 2016; Krägeloh, Czuba, Billington, 
Kersten, & Siegert, 2015). This survey confirms other surveys (Read, Cartwright, et al., 2014; 
2018; R.C.P., 2012), and the recent systematic review (Davies & Read, 2019a), in finding 
that more than half of people experience withdrawal effects when trying to come off, or 
reduce, ADs, and shows that at least two specific effects, and some degree of difficulty 
coming off, are also experienced by more than half.  
All these findings were fed into Public Health England’s inquiry into dependence on 
prescribed drugs (Taylor et al., 2019), and to the recently announced review of NICE 
guidelines  for antidepressants (Davies et al., 2019; Hengartner, Davies & Read, 2019). In 
May 2019 The Royal College of Psychiatry published a new position statement, which 
included: 
To ensure informed consent and shared decision-making, the use of antidepressants should 
always be underpinned by a discussion with the patient, and family/carer (as appropriate), 
about the potential level of benefits and harms, including withdrawal. . . . Discontinuation 
of antidepressants should involve the dosage being tapered or slowly decreased to reduce 
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the risk of distressing symptoms, which may occur over several months (R.C.P., 2019, pp. 
1,2). 
 
In September, 2019 Public Health England published its report (Taylor et al.) It found that: 
‘Antidepressants are associated with withdrawal. Seventeen placebo-controlled trials (with 
6,729 participants) show that withdrawal symptoms, such as insomnia, depression, suicidal 
ideation and physical symptoms, follow when patients stop taking medication’. (p 14). On the 
basis of these findings, and the Davies and Read (2019a) review, the report made vitally 
important recommendations in five areas for the drugs concerned, including antideressants: 
 
1. Increasing the availability and use of data on the prescribing of medicines that can cause 
dependence or withdrawal..  
2. Enhancing clinical guidance and the likelihood it will be followed.  
3. Improving information for patients and carers on prescribed medicines and other 
treatments, and increasing informed choice and shared decision making between clinicians 
and patients.  
4. Improving the support available from the healthcare system for patients experiencing 
dependence on, or withdrawal from, prescribed medicines.  
5. Further research on the prevention and treatment of dependence on, and withdrawal 
from, prescribed medicines. (p. 120). 
 
We may finally be on the verge of GPs being provided with evidence-based information, 
and patients being offered appropriate advice about gradual tapering (Groot & van Os, 2018; 
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women younger treatment 
duration 
Anxiety/Panic 65.6% 31.7% 33.9%   *** 
Irritability 62.5% 31.8% 30.7%   *** 
Dizziness 43.9% 20.5% 23.4% ** *** *** 
Brain Zaps 42.5% 18.0% 24.5%  *** *** 
Nightmares 36.7% 19.9% 16.8%  ** *** 
Nausea 34.8% 18.9% 15.9%  *** ** 
 
1: n from 787 to 798 
** < .01 





‘Other’ withdrawal effects mentioned by four or more participants. 
Suicidal thoughts 19 Sweating  6 
Insomnia  14 Visual disturbances 6 
Pain/Aches 13 Crying  6 
Sexual dysfunction 12 Twitches/tics 5 
Anger/rage/aggressive 10 Spasms/cramps 5 
Dissociation/depersonalisation  8 Body zaps 5 
Diarrhea  8 Vertigo 5 
Fatigue/exhaustion  8 Headaches 4 
Akathisia/restless legs 7 ‘Flu-like’ symptoms 4 
Tremors/shakes 7 Sensitivity to light/sound 4 





Table 3  











All (n = 797) 27.2% 13.2% 14.2% 20.6% 13.9% 10.9%  54.6% 
         
Men  
(n = 228) 
22.4% 12.3% 15.4% 23.7% 13.6% 12.7%  50.4% 
Women  
(n = 562) 
29.4% 13.5% 13.3% 19.2% 14.2% 10.3%  56.2% 
         
Took ADs <  1 
year  (n = 199) 
8.0% 5.5% 11.6% 28.6%% 21.6% 24.6%  25.1% 
Took ADS > 3 
years *** 
(n = 462) 
38.3% 16.9% 13.4% 17.3% 9.5% 4.5%  68.6% 
         
Mean age 
(n = 796) 
44.1 45.8 44.4 47.0 46.3 46.2   
 









 Withdrawal effects, addiction and ‘difficulty coming off, by drug types. 
 
 Paroxetine 
n = 59 
Venlafaxine 
n = 51 
Fluoxetine 
n = 111 
Escitalopram 
n = 48 
Citalopram 







74.6% 76.5% 64.9% 64.6% 62.0% 55.9% 72.0% 
        
Anxiety/ 
Panic 
89.5% C t s 70.0% 72.7% 75.0% 64.3% 67.3% 66.0% 
Irritability 79.3% t 76.0% 72.5% 72.9% 66.7% 62.7% 54.0% 
Dizziness 71.4% S T f 60.0% 46.8% 52.1% 52.0% 42.2% 38.8% 
Brain Zaps 69.0% S C T f 64.0% s t 46.2% 53.2% 41.8% 38.6% 36.7% 
Nightmares 60.0% S c t f 46.0% 35.2% 43.8% 37.5% 26.5% 32.7% 
Nausea 57.9% S F t 48.0% 30.8% 44.7% 42.3% 27.5% 28.0% 
        
Addiction 49.2% 45.1% 41.4% 37.5% 33.0% 37.3% 46.0% 
        
Some 
difficulty 
76.3% S C T f 70.0% 62.7% 62.5% 55.6% 52.0% 52.0% 
 
C < .001 greater than citalopram; c < .01 greater than citalopram 
F < .001 greater than fluoxetine;  f < .01 greater than fluoxetine 
S < .001 greater than sertraline;   s < .01 greater than sertraline 
T < .001 greater than tricyclics;   t < .01 greater than tricyclics 
 
 
 
 
 
